OCUP (MKap $58 M) Low floater mit 2x Phase 3 Assets (Seite 5)
eröffnet am 28.12.20 20:38:32 von
neuester Beitrag 08.01.24 13:49:16 von
neuester Beitrag 08.01.24 13:49:16 von
Beiträge: 213
ID: 1.337.181
ID: 1.337.181
Aufrufe heute: 0
Gesamt: 25.731
Gesamt: 25.731
Aktive User: 0
ISIN: US67577R1023 · WKN: A2QG4Z · Symbol: R3X1
1,5920
EUR
-11,36 %
-0,2040 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
10.05.24 · globenewswire  |
06.05.24 · globenewswire |
03.05.24 · globenewswire |
22.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 141,00 | +41,00 | |
| 1,0000 | +33,33 | |
| 6,5900 | +31,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 12,150 | -12,72 | |
| 35,69 | -13,71 | |
| 29,40 | -16,95 | |
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 |
Beitrag zu dieser Diskussion schreiben
FeedbackOcuphire Corporate Presentation November 2022
# F & F neue presie imho lesenswert - incl neuem dealhttps://d1io3yog0oux5.cloudfront.net/_12f7136f1b14d16a132738…
Antwort auf Beitrag Nr.: 72.441.657 von M@trix am 21.09.22 19:01:30würde mich freuen @M@trix wenn du dich jetzt nach dem deal zur situation äußern würdest.
liegen Gruss
liegen Gruss
Guten Tag,
Bin heute bei 2.25 Euro neu eingestiegen und wüsste gerne warum die Aktie noch so günstig ist bei einer so niedrigen MK und einer Upfront über 35 Mio.
Wäre sehr dankbar über Meinungen.
Inflation und krieg ist bekannt, meine Meinungen die mit dem Unternehmen zu tun haben.
Vielen Dank an alle
Bin heute bei 2.25 Euro neu eingestiegen und wüsste gerne warum die Aktie noch so günstig ist bei einer so niedrigen MK und einer Upfront über 35 Mio.
Wäre sehr dankbar über Meinungen.
Inflation und krieg ist bekannt, meine Meinungen die mit dem Unternehmen zu tun haben.
Vielen Dank an alle
Pursuant to the License Agreement, Famy will make to Ocuphire an upfront cash payment of $35 million.
In addition, with respect to each Product, Ocuphire will be eligible to receive potential additional payments of up to $130 million in the aggregate upon achieving certain specified regulatory or net sales milestones, with the first potential payment of $10 million to be made following approval by the FDA of Nyxol for reversal of mydriasis.
Ocuphire will also receive tiered royalties, starting at low double digit royalties up to low twenty percent royalties, based on the aggregate annual net sales of all Products in the United States, and will receive low double digit royalties based on all annual net sales in the Territory outside of the United States. The royalty payments will continue on a country-by-country basis from the date of the first commercial sale of the first Product in a country of the Territory until December 31, 2040.
https://de.advfn.com/borse/NASDAQ/OCUP/nachrichten/89486277/…
In addition, with respect to each Product, Ocuphire will be eligible to receive potential additional payments of up to $130 million in the aggregate upon achieving certain specified regulatory or net sales milestones, with the first potential payment of $10 million to be made following approval by the FDA of Nyxol for reversal of mydriasis.
Ocuphire will also receive tiered royalties, starting at low double digit royalties up to low twenty percent royalties, based on the aggregate annual net sales of all Products in the United States, and will receive low double digit royalties based on all annual net sales in the Territory outside of the United States. The royalty payments will continue on a country-by-country basis from the date of the first commercial sale of the first Product in a country of the Territory until December 31, 2040.
https://de.advfn.com/borse/NASDAQ/OCUP/nachrichten/89486277/…
Trading Spotlight
Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. (Famy) for the development and commercialization of Nyxol across three indications in US, Europe, Japan, India, China and other global markets. In connection with its separately announced transaction with Famy, Viatris Inc. (Nasdaq: VTRS), a leading global healthcare company, has agreed to commercialize Nyxol following each regulatory approval.
https://finance.yahoo.com/news/ocuphire-pharma-enters-global…
Viatris Reports Strong Third Quarter 2022 Results
Reports Total Revenues of $4.08 billion; U.S. GAAP Net Earnings of $354 million;
Adjusted EBITDA of $1.50 billion; U.S. GAAP Net Cash Provided by Operating Activities of $869 million;
and Free Cash Flow of $765 million
https://finance.yahoo.com/news/viatris-reports-strong-third-…
https://finance.yahoo.com/news/ocuphire-pharma-enters-global…
Viatris Reports Strong Third Quarter 2022 Results
Reports Total Revenues of $4.08 billion; U.S. GAAP Net Earnings of $354 million;
Adjusted EBITDA of $1.50 billion; U.S. GAAP Net Cash Provided by Operating Activities of $869 million;
and Free Cash Flow of $765 million
https://finance.yahoo.com/news/viatris-reports-strong-third-…
Global License Agreement
# F & FOcuphire Pharma Enters into a Global License Agreement for Development and Commercialization of
Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
Ocuphire to Receive $ 35 Million Upfront, Nyxol Development Funding and
Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
Strengthened Financial Position Supports Operations and APX3330 Program into 2025
Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. (Famy) for the development and commercialization of Nyxol across three indications in US, Europe, Japan, India, China and other global markets. In connection with its separately announced transaction with Famy, Viatris Inc. (Nasdaq: VTRS), a leading global healthcare company, has agreed to commercialize Nyxol following each regulatory approval.
Under the terms of the license agreement, Ocuphire will receive an upfront cash payment of $35 million. Famy will fund Nyxol development through FDA approvals, that will be managed by Ocuphire, including clinical, manufacturing, and regulatory activities required for FDA approval of all three Nyxol indications, including Nyxol+Low-Dose Pilocarpine. With the upcoming NDA submission for the reversal of mydriasis indication this quarter, Ocuphire has the potential to receive a $10 million milestone payment upon FDA approval later in 2023 and thereafter to receive additional regulatory milestones for presbyopia and night vision disturbances indications. In addition to funding Ocuphire’s development of Nxyol in the US, Famy will undertake development in the non-US markets.
Upon commercialization, Ocuphire will receive tiered double-digit royalties on worldwide net sales through 2040 and is eligible to receive sales milestone payments upon achievement of certain annual sales thresholds.
https://finance.yahoo.com/news/ocuphire-pharma-enters-global…
VTRS - Viatris Inc. Market Cap 13.303B
https://finance.yahoo.com/quote/VTRS?p=VTRS&.tsrc=fin-srch
# F & F
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early 2023
“With enrollment and 24-week treatment completed in over 100 patients in our ZETA-1 Phase 2b trial of APX3330, we look forward to sharing topline results in early 2023, bringing us closer to delivering a potential oral option for diabetic retinopathy patients. We are on track for NDA submission for Nyxol for reversal of mydriasis in the fourth quarter 2022. We have strong momentum and are poised to deliver on multiple catalysts going forward that we believe will create significant value for our company and shareholders.”
Presbyopia: Plan to initiate VEGA-2 Phase 3 trial in Q4 2022 investigating Nyxol alone and Nyxol with 0.4% low-dose pilocarpine (LDP) as adjunctive therapy. In addition, VEGA-3 (2nd Phase 3) and LYRA-1 (1-year safety) trials are planned to begin in 2023.
As of September 30, 2022, Ocuphire had cash and cash equivalents of approximately $13.9 million.
Based on current projections, management believes the current cash on hand will be sufficient
to fund operations into the fourth quarter of 2023
https://finance.yahoo.com/news/ocuphire-pharma-announces-fin…
Danke Matrix
für deinen Post. Schade hast du nicht alle Stücke bekommen. Ich setze auch grosse Hoffnungen in Q4 und bin auch der Meinung, dass die Kursziele von bis zu 26 USD nicht unrealistisch sind, sollten keine negativen Überraschungen kommen...😋
Den Rest habe ich nicht mehr bekommen, werde aber definitiv weiter zukaufen, sofern wir nochmal Richtung 2 USD fallen. In Q4 stehen mehrere bedeutende Meilensteine an:
- NDA Nyxol
- Phase 2b Daten für APX3330 -> https://clinicaltrials.gov/ct2/show/NCT04692688
Spätestens mit der Einreichung des NDA geht die Verpartnerung in die heiße Phase. Und da OCUP bis ins zweite Halbjahr 2023 kein Kapital braucht, können sie da sehr entspannt verhandeln.
Ich glaube fest, dass OCUP auf dem aktuellen Niveau eine reale Chance auf eine Verzehnfachung bietet binnen 12-18 Monaten. Natürlich klingt das wir "Pusherei", aber ich komme eben einfach zu diesem Ergebnis. Selten habe ich eine Biotech-Aktie mit einem solch exzellenten Chance/Risiko-Verhältnis gesehen. Alles was es braucht ist Geduld.
M@trix
- NDA Nyxol
- Phase 2b Daten für APX3330 -> https://clinicaltrials.gov/ct2/show/NCT04692688
Spätestens mit der Einreichung des NDA geht die Verpartnerung in die heiße Phase. Und da OCUP bis ins zweite Halbjahr 2023 kein Kapital braucht, können sie da sehr entspannt verhandeln.
Ich glaube fest, dass OCUP auf dem aktuellen Niveau eine reale Chance auf eine Verzehnfachung bietet binnen 12-18 Monaten. Natürlich klingt das wir "Pusherei", aber ich komme eben einfach zu diesem Ergebnis. Selten habe ich eine Biotech-Aktie mit einem solch exzellenten Chance/Risiko-Verhältnis gesehen. Alles was es braucht ist Geduld.
M@trix
Durchsuchen
| Zeit | Titel |
|---|---|
| 10.05.24 |